Daiichi Sankyo’s European division is teaming up with German medtech Gaia to sell the latter company’s cardiovascular digital therapeutic lipodia. | Daiichi Sankyo’s European division is teaming up ...

Sankyo Tateyama (TSE:5932) remains in the red, with losses increasing at an annualized pace of 32.5% over the last five years. While the company’s net profit margin has shown no improvement during ...

Hiroyuki Okuzawa will step into the role starting in April. Daiichi Sankyo announced that Hiroyuki Okuzawa will serve as its new CEO starting on April 1, 2025. 1 The previous CEO, Sunao Manabe, DVM, ...

Daiichi Sankyo recently reported several developments, including European Medicines Agency validation of a Type II variation filing for ENHERTU in early‑stage HER2 positive breast cancer, a new ...

GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval 1. This press ...

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025. Dr.

Every year, April brings the peak bloom period for cherry blossom trees — and one pharma company is tying its involvement with the springtime ritual to its efforts in the oncology space. Japanese ...

Masahiro Kato takes over as Managing Director, Oliver Appelhans appointed to Head of the European Specialty Business Unit MUNICH--(BUSINESS WIRE)--Today, Daiichi Sankyo Europe GmbH, the European ...

Daiichi Sankyo’s antibody-drug conjugate (ADC) platform has already delivered one drug to the market with blockbuster sales forecasts, with a second due to be filed shortly. Now, a third is showing ...

Setbacks sometimes prompt a great leap forward. For Sankyo, a major product withdrawal-most painfully, of its potential blockbuster for diabetes, Rezulin (troglitazone)-created the reversal. Major ...

Daiichi Sankyo is in talks with several companies over a sale of its over-the-counter (OTC) business, according to press reports. Citing Nikkei Business, Reuters reported that the final price is ...

Daiichi Sankyo submits Enhertu sNDA in Japan as adjuvant therapy for patients with HER2 positive early breast cancer: Tokyo Monday, March 2, 2026, 12:00 Hrs [IST] Daiichi Sankyo h ...